New Oral Treatments for Asthma through Tissue-Specific Modulation of the GABAA Receptor

New Oral Treatments for Asthma through Tissue-Specific Modulation of the GABAA Receptor

Conclusions α4 and α5-selective GABAAR modulators have a great potential as novel orally active drug candidates for asthma to alleviate symptoms of airway hyperresponsiveness mediated by ASM constriction, hypereosinophilia, and inflammation.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2017-02, Vol.139 (2), p.AB9-AB9
Hauptverfasser: Arnold, Leggy, Forkuo, Gloria, Nieman, Amanda, Yu, Olivia B, Guthrie, Margaret L, Kodali, Revathi, Yuan, Nina, Jahan, Rajwana, Stephen, Michael S, Emala, Charles W, Yocum, Gene T, Cook, James M, Grayson, Mitchell H., MD, FAAAAI
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Asthma
Ligands
Rodents
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Conclusions α4 and α5-selective GABAAR modulators have a great potential as novel orally active drug candidates for asthma to alleviate symptoms of airway hyperresponsiveness mediated by ASM constriction, hypereosinophilia, and inflammation.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.12.083